摘要
目的:评价替米沙坦对IgA肾病患者蛋白尿的影响。方法:选择30例IgA肾病患者为研究对象,将其随机分为治疗组和对照组各15例,治疗组应用替米沙坦治疗,对照组应用常规治疗。观察时间为6个月。观察24h尿蛋白定量、血压变化、血肌酐、尿素氮的变化。结果:治疗6个月后,治疗组与对照组24h尿蛋白均减少,治疗组较对照组疗效更显著。结论:替米沙坦能够减少IgA肾病患者尿蛋白量,对阻止和延缓疾病的进展、减少终末期肾病的发生率具有较好的作用。
Objective：To evaluate the efficacy of telmisartan on IgA nephropathy proteinuria.Methods：30 cases of patients with IgA nephropathy were randomly divided into two groups,the treatment group 15 cases were given telmisartan treatment,the control group 15 cases were given conventional treatment.Observed 6 months.Observed the 24-hour urine protein quantification,blood,serum creatinine,urea nitrogen.Results：After 6 months treatment,the 24-hour urine protein of the treatment group and the control group both decreased,the effect of the treatment group was better than that of the control group.Conclusion：Telmisartan can reduce urine protein of IgA nephropathy,it has good effects to block and slow down the progress of the disease,reduce end-stage renal disease incidence.
出处
《中国当代医药》
2010年第30期43-44,共2页
China Modern Medicine
